A recently released guidance to industry and US Food and Drug Administration staff, called “Pharmacogenetic Tests and Genetic Tests for Heritable Markers,” is not explicit enough in outlining when diagnostic companies will need to apply for premarket approval and when a 510(k) clearance will be sufficient, according to a lawyer representing the interests of diagnostic companies, patient groups, and investors.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try GenomeWeb Premium now.
You may already have institutional access!
Check if I qualify.
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.